SCHEMBL4714992

SCHEMBL4714992

Cc1cc(C)nc(-c2c[c]ccc2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
NOS3 P29474 2/20 0.34
NOS2 P35228 2/20 0.34
NOS1 P29475 1/20 0.34
MAPT P10636 5/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
KMT2A Q03164 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
ADORA1 P30542 3/20 0.33
ADORA2A P29274 3/20 0.33
TSHR P16473 1/20 0.33
ATM Q13315 1/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
NFKB1 P19838 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2875294 0.79 CCR1 (0.54) RAB9ANOS3NOS2MEN1KMT2A
SCHEMBL23927532 0.78 ADORA2A (0.38) KDM4ENPC1RAB9AMAPTMEN1
SCHEMBL9958076 0.78 MEN1 (0.39) KDM4ERAB9AMAPTMEN1ALDH1A1
SCHEMBL3848271 0.77 KMT2A (0.53) KDM4ENPC1RAB9AMAPTMEN1
SCHEMBL27764808 0.77 RAD51 (0.42) KDM4ENPC1RAB9AMAPTALDH1A1
SCHEMBL9957627 0.77 LMNA (0.46) KDM4ENPC1RAB9AMAPTMEN1
SCHEMBL4555939 0.76 CYP2A6 (0.56) KDM4ENOS3NOS2NOS1MEN1
SCHEMBL27764850 0.75 KIF11 (0.40) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL9957875 0.75 MEN1 (0.51) KDM4ENPC1RAB9AMAPTMEN1
SCHEMBL3851837 0.74 RAB9A (0.58) KDM4ENPC1RAB9AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1248612-B1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA LTD (CA) 2008-02-27 EP disclosed
EP-1248612-A4 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2005-09-07 EP disclosed
US-6525036-B2 Treating post-menopausal osteoporosis. MERCK & CO., INC. 2003-02-25 US disclosed
EP-1248612-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA INC. (CA) 2002-10-16 EP disclosed
WO-2002070519-A1 MONOBACTAMS AS CATHEPSIN K INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-09-12 WO disclosed
US-20020052378-A1 Novel compounds and compositions as protease inhibitors Celera Corporation 2002-05-02 US disclosed
WO-2001049288-A9 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2001-10-25 WO disclosed
WO-2001049288-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052378-A1 Novel compounds and compositions as protease inhibitors SERPINB1, CTRL, SPINT2 KDM4E 3906/4885NPC1 330/4885RAB9A 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.